[HTML][HTML] Erlotinib in lung cancer—molecular and clinical predictors of outcome
…, F Richardson, L Seymour, M Whitehead… - … England Journal of …, 2005 - Mass Medical Soc
Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …
[PDF][PDF] Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
…, N Liu, T Zhang, P Marrano, M Whitehead… - Journal of clinical …, 2008 - researchgate.net
… Chang-Qi Zhu, Gilda da Cunha Santos, Keyue Ding, Akira Sakurada, Jean-Claude Cutz,
Ni Liu, Tong Zhang, Paula Marrano, Marlo Whitehead, Jeremy A. Squire, Suzanne Kamel-Reid …
Ni Liu, Tong Zhang, Paula Marrano, Marlo Whitehead, Jeremy A. Squire, Suzanne Kamel-Reid …
[PDF][PDF] Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer
…, D Lau, N Liu, A Sakurada, M Whitehead… - Journal of clinical …, 2007 - academia.edu
Results Of 253 patients, 132 (52%) were positive for p53 protein overexpression. Untreated
p53-positive patients had significantly shorter overall survival than did patients with p53-…
p53-positive patients had significantly shorter overall survival than did patients with p53-…
[PDF][PDF] Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical …
…, NB Leighl, TL Winton, M Whitehead… - Journal of Clinical …, 2008 - researchgate.net
Purpose This study analyzed patients enrolled in two large, prospectively randomized trials
of systemic chemotherapy (adjuvant/palliative setting) for non–small-cell lung Cancer (…
of systemic chemotherapy (adjuvant/palliative setting) for non–small-cell lung Cancer (…
[PDF][PDF] Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation …
…, CW Lee, M Djurfeldt, M Whitehead… - Journal of Clinical …, 2007 - researchgate.net
… Lee, Marina Djurfeldt, Marlo Whitehead, Peter Ellis, Glenwood Goss, Adrien Chan, Jacinta
Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, and Frances …
Meharchand, Yasmin Alam, Richard Gregg, Charles Butts, Peter Langmuir, and Frances …
Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non–small cell lung cancer: analysis of NCIC JBR. 10
…, S Aviel-Ronen, L Seymour, M Whitehead… - Clinical cancer …, 2007 - AACR
Purpose: High class III β-tubulin (bTubIII) expression in advanced non–small cell lung
cancer is known to correlate with reduced response rates and inferior survival with anti-…
cancer is known to correlate with reduced response rates and inferior survival with anti-…
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non–small-cell lung cancer in the …
…, P Santabárbara, K Ding, M Whitehead… - Clinical lung cancer, 2006 - Elsevier
Background Erlotinib is an oral, reversible inhibitor of the HER1/epidermal growth factor
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo was …
receptor (EGFR) tyrosine kinase. A survival advantage for erlotinib compared with placebo was …
Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: An analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 …
…, D Johnson, R Livingston, J Rigas, M Whitehead… - Lung Cancer, 2005 - Elsevier
Resected non-small cell lung cancer (NSCLC) has 5-years survival rates of 30–70%. The
role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. …
role of adjuvant chemotherapy remains unclear with poor compliance reported in most trials. …
Body mass index, outcomes, and mortality following cardiac surgery in Ontario, Canada
Background The “obesity paradox” reflects an observed relationship between obesity and
decreased morbidity and mortality, suggesting improved health outcomes for obese individuals…
decreased morbidity and mortality, suggesting improved health outcomes for obese individuals…
[HTML][HTML] Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib
…, DM Zborowski, JL Culbertson, M Whitehead… - Journal of Thoracic …, 2006 - Elsevier
Introduction Erlotinib (Tarceva®) has demonstrated a survival benefit in unselected patients
with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because …
with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because …
